Predict your next investment

HEALTHCARE | Medical Facilities & Services / Medical Laboratories & Research
hritrials.com

See what CB Insights has to offer

Stage

Merger | Merged

About Hassman Research Institute

Hassman Research Institute operates as a clinical research organization that conducts studies in a wide variety of therapeutic areas.

Hassman Research Institute Headquarter Location

175 Cross Keys Rd

Berlin, New Jersey, 08009,

United States

856-566-9000

Latest Hassman Research Institute News

Email to a friend Follow us on Twitter Follow us on Facebook Follow us on LinkedIn New clinical trial firm formed following 3-company merger

Oct 8, 2019

By Melissa Fassbender Three organizations have merged to form Apex Innovative Sciences, an independent clinical trial site operator focused on Phase I-IV studies for central nervous system indications and other therapeutic areas, including neurology, psychiatry, addiction, and others. CNS Network and the Hassman Research Institute (HRI) recently completed a strategic merger to form Apex Innovative Sciences (Apex), which in turn acquired the Clinical Trial Centers Alliance (The Alliance). James Castro, managing director of FocalPoint Partners (FPP), said the investment bank approached each business owner with the consolidation strategy. Speaking to the deal rationale, Castro told us CA-based CNS Networks provides Phase II and III inpatient clinical trial services, with expertise in clinical neuroscience indications, such as schizophrenia. Said Castro, “Phase II and III inpatient studies for these complex clinical neuroscience studies involves an acute subject population which not many sites can manage well. CNS can fill studies with subjects quickly given its proprietary database of over 150,000 potential study candidates.”​ Supplementing these services, Castro said the Hassman Research Institute is ‘largely recognized’ for its early phase work and has broader experience in various indications, including addiction, general medicine, dermatology, clinical neuroscience, among others. The third of the recently merged companies, the Clinical Trials Centers Alliance (The Alliance), has “an expansive base of relationships with pharma and biotech sponsors,” ​added Castro. “The company identifies new studies and ‘pitches’ its third-party network of sites to provide site-level clinical research services. The Alliance often combines CNS’s and HRI’s complementary services to win new, large, national studies,”​ he said. The combined entity will operate under the Apex Innovative Sciences name and is currently centralizing The Alliance’s database across all the organizations. Over the next several months, the new company also will look to acquire additional sites, said Castro. “Apex Innovative Sciences will look to separately accelerate the growth of its Acute Psychiatric Hospital,” ​he added. “Behavioral health companies have already demonstrated interest in separately purchasing the APH from Apex.”​ Dr. Howard Hassman, Apex CEO said in a statement: “This combination is the culmination of years of collaboration between our organizations in complex clinical trial studies.”​ Bison Capital Partners also participated with an equity investment to help expand Apex’s behavioral health treatment facility programs. Copyright - Unless otherwise stated all contents of this web site are © 2020 - William Reed Business Media Ltd - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.